Every Form 4 that Takeda Pharmaceutical Co Ltd (TKPHF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TKPHF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TKPHF filings page.
TAKEDA PHARMACEUTICAL CO LTD (TAK) reported that Andrew Stewart Plump, its President of R&D and a director, sold 116,191 American Depositary Shares on September 2, 2026 at $18.49 per share through a trust. The trust held 145,465 ADS after the sale, and he also reported 766,569 ADS held directly. The sale was made under a Rule 10b5-1 trading plan adopted on May 15, 2026.
TAKEDA PHARMACEUTICAL CO LTD (TAK) director and officer Andrew Stewart Plump, President, R&D, reported the sale of 19,651 American Depositary Shares of Takeda on August 19, 2026 at $18.49 per ADS. The shares were held indirectly by a trust, which held 261,656 ADS afterward. Separately, Plump reported 766,569 ADS held directly following the reported transactions. The sale was effected under a Rule 10b5-1 trading plan adopted on May 15, 2026.
TAKEDA PHARMACEUTICAL CO LTD (TAK) reported an insider share sale by Chief Human Resources Officer Nicola Deidre Petal Greenway. On 2026-08-18, she sold 12,980 American Depositary Shares at $18.1139 per share in an open market or private transaction, and 40,049 ADS remain held directly.
Takeda Pharmaceutical Co. Ltd. reports that Chief Medical Officer Farajallah Awny Samaan Botros sold 14,006 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. The transaction represents a mandatory sale to cover taxes tied to vesting equity awards. Following this sale, Botros directly holds 116,177 American Depositary Shares.
Takeda Pharmaceutical Co Ltd executive Ramy Riad Ahmed, President of the PDT business unit, reported a sale of 7,277 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. A footnote states this was a mandatory sale to cover taxes related to the vesting of equity awards. Following this transaction, Ahmed directly holds 102,588 American Depositary Shares.
Takeda Pharmaceutical Co Ltd executive Rhonda Janice Pacheco, President, U.S. Business Unit, reported the sale of 16,901 American Depositary Shares on 2026-08-10. The transaction was a mandatory sale to cover taxes triggered by vesting of equity awards, executed at a $17.10 weighted average price per ADS. Following this tax-related sale, she directly holds 182,507 ADS.
TAKEDA PHARMACEUTICAL CO LTD executive Lauren Rusckowski Duprey, Chief Transformation Officer, reported selling 47,586 American Depositary Shares on 2026-08-10. The sale was described as a mandatory sale to cover taxes associated with vesting of equity awards. The reported $17.10 figure is a weighted average price for the transaction. After this sale, Duprey directly held 226,057 American Depositary Shares.
TAKEDA PHARMACEUTICAL CO LTD director and President, R&D Andrew Stewart Plump reported a sale of 165,393 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. The transaction was a mandatory sale to cover taxes tied to vesting equity awards. Following this sale, he holds 766,569 ADSs directly and 281,307 ADSs indirectly through a trust.
Takeda Pharmaceutical Co Ltd executive Marcello Pignagnoli, Head of Strategic & Portfolio Development, reported a sale of 22,957 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. According to the disclosure, this was a mandatory sale to cover taxes associated with the vesting of equity awards. Following the transaction, Pignagnoli directly held 176,977 ADS.
Takeda Pharmaceutical executive Teresa Marie Bitetti, President of OBU, reported selling 50,012 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. A footnote states this was a mandatory sale to cover taxes on vesting equity awards. She now directly holds 252,010 ADS.
Takeda Pharmaceutical Co Ltd reports that executive Shannon Elaine Mary, President, Global Supply & Quality, sold 3,978 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. The company notes this was a mandatory sale to cover taxes associated with vesting equity awards. After the transaction, Mary held 63,333 ADSs directly.
Takeda Pharmaceutical Co Ltd executive Gabriele Ricci, Chief Data & Tech. Officer, reported a sale of 25,088 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. The transaction was a mandatory sale to cover taxes tied to vesting equity awards, and Ricci now directly holds 171,654 ADSs.
Takeda Pharmaceutical (TAK) executive Nicola Deidre Petal Greenway, Chief Human Resources Officer, reported selling 6,774 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. The transaction was a mandatory sale to cover taxes tied to vesting equity awards. After this sale, she directly holds 53,029 ADS.
Takeda Pharmaceutical Co Ltd President and CEO Julie So-Young Kim reported selling 89,090 American Depositary Shares on August 10, 2026 at a weighted average price of $17.10 per share. The company states this was a mandatory sale to cover taxes on vesting equity awards, leaving her with 391,489 ADS held directly.
TAKEDA PHARMACEUTICAL CO LTD executive Giles Richard Platford, President, IBU, reported a sale of 31,083 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per share. According to the disclosure, this was a mandatory sale to cover taxes tied to the vesting of equity awards, and his direct holdings after the transaction were 315,838 ADSs. The transaction was reported as a sale in the open market or a private transaction and was not marked as executed under a Rule 10b5-1 trading plan.
Takeda Pharmaceutical Co. Ltd. reported that its Global General Counsel, Natalie Anne Marie Furney, executed a sale of 30,868 American Depositary Shares on August 10, 2026. The sale, at a weighted average price of $17.10 per ADS, was a mandatory sale to cover taxes associated with the vesting of equity awards. Following this transaction, Furney directly holds 204,298 ADSs of Takeda.
Takeda Pharmaceutical Co. Ltd. reported that Shannon Elaine Mary, Pres., Global Supply & Quality, sold 20,363 American Depositary Shares on 2026-08-11 in a sale categorized as an open market or private transaction at $17.55 per ADS. Following this sale, she directly holds 67,311 ADS.
Takeda Pharmaceutical Co Ltd officer Nicola Deidre Petal Greenway, Chief Human Resources Officer, reported selling a total of 34,603 American Depositary Shares of Takeda on 2026-08-10. The sales were reported as open-market or private transactions at prices around $17.50 per ADS, with direct ownership status.
Takeda Pharmaceutical director Steven Gillis reported compensation-related equity awards and a tax settlement. On July 1, 2026, he received 3,800 Ordinary Shares as a grant and 1,319 "Tax Obligation Awards," each economically equivalent to one Ordinary Share and intended to be cash-settled at vesting mainly to cover tax obligations.
The filing notes an earlier RSU vesting where 3,100 Ordinary Shares were converted into 6,200 American Depositary Shares. On July 10, 2026, 1,152 Tax Obligation Awards were disposed of to the issuer, with the associated Ordinary Shares sold at a weighted average of JPY 4,931.2 per share; remaining proceeds from those sales are to be delivered to Gillis. Following these events, he holds 22,057 American Depositary Shares directly, and the RSU and Tax Obligation Awards are scheduled to vest on June 1, 2029.
Takeda Pharmaceutical director John Maraganore reported equity compensation and related tax settlements. He received 3,800 Ordinary Shares as a grant and 1,319 Tax Obligation Awards, each tied to one Ordinary Share that will vest and convert on June 1, 2029. A prior block of 1,152 Tax Obligation Awards, economically equivalent to 1,152 Ordinary Shares, was disposed to the issuer at a weighted average price of JPY 4,931.2 per share, primarily to cover tax obligations. Following these events, he directly holds 10,400 Ordinary Shares and 13,800 American Depositary Shares.
Takeda Pharmaceutical director Kimberly A. Reed reported new equity awards and related tax transactions. She received a grant of 3,800 Ordinary Shares as restricted stock units that vest on June 1, 2029, plus 1,319 Tax Obligation Awards economically equivalent to Ordinary Shares vesting on the same date.
Separately, 1,152 Tax Obligation Awards tied to Ordinary Shares were disposed of at a weighted average price of JPY 4,931.2 per share, primarily to cover tax obligations, with any remaining cash proceeds to be delivered to her on July 10. After these updates, she directly holds 10,400 Ordinary Shares and 15,175 American Depositary Shares.
Takeda Pharmaceutical director Masami Iijima reported compensation-related equity activity. On July 1, he received a grant of 1,800 Ordinary Shares as a restricted stock unit award, increasing his direct holdings to 14,601 shares. The RSUs vest on June 1, 2029.
He also received 1,937 Tax Obligation Awards, each economically equivalent to one Ordinary Share and payable in cash at vesting primarily to cover tax obligations at the then-current market price. Separately, 2,152 Tax Obligation Awards tied to previously vested shares were disposed to the issuer on July 10 at a weighted average price of JPY 4,931.2 per share, with any remaining sale proceeds to be delivered to him.
Takeda Pharmaceutical Co. Ltd. director Bruce D. Broussard received equity-based compensation rather than buying shares on the market. He was granted 3,800 American Depositary Shares (ADS) on a cost-free basis, increasing his direct holdings to 4,595 ADS after the award.
The grant represents restricted stock units (RSUs), each linked to one Ordinary Share that will convert into an equivalent number of ADS when the award vests on June 1, 2029. These RSUs are contingent and only settle if vesting conditions are met.
Broussard was also granted 1,319 units of a Tax Obligation Award, economically equivalent to one Ordinary Share each. Upon vesting on June 1, 2029, these are designed to pay cash at the then-current market price primarily to cover related tax obligations, rather than delivering additional shares.
Takeda Pharmaceutical director Paulus Stoffels reported an equity compensation grant. He acquired 3,800 Ordinary Shares on a grant or award basis, bringing his directly held Ordinary Shares to 3,800.
He was also granted 1,307 Tax Obligation Awards, each economically equivalent to one Ordinary Share. The related restricted stock units vest on June 1, 2029 and will convert into Ordinary Shares, which are then deliverable as American Depositary Shares. The Tax Obligation Awards are structured to pay cash at vest, primarily to cover tax obligations based on the then-current market price.
Takeda Pharmaceutical director Kimura Koichiro received new equity-based compensation tied to Ordinary Shares. He was granted 1,800 Ordinary Shares on an award basis at a price of $0.00 per share, bringing his directly held Ordinary Shares to 1,800.
He also received 1,937 units of a Tax Obligation Award, each economically equivalent to one Ordinary Share. According to the disclosure, the 1,800-share award represents restricted stock units that vest on June 1, 2029, while the 1,937-unit Tax Obligation Award will convert to a cash payment at vest primarily to cover tax obligations at the then-current market price.
Takeda Pharmaceutical director Miki Tsusaka reported routine equity compensation and tax-related transactions. She received a grant of 1,800 Ordinary Shares, bringing her direct holdings to 8,200 shares. She was also granted 1,937 Tax Obligation Awards, each economically equivalent to one Ordinary Share and scheduled to vest on June 1, 2029.
In a separate move, 2,152 Tax Obligation Awards were disposed of to the issuer after vesting, converting into a cash payment primarily to cover tax obligations. The associated Ordinary Shares were sold at a weighted average price of JPY 4,931.2, within a range from JPY 4,883 to JPY 5,045, with any remaining proceeds delivered to her on July 10.
Takeda Pharmaceutical's President, Japan Pharma Business Unit, Asuka Miyabashira reported routine equity compensation and related tax-settlement activity. Miyabashira acquired 1,500 Ordinary Shares as a share grant, bringing direct ownership to 4,500 shares after the transaction. On the same date, Miyabashira also received several Tax Obligation Awards, each economically equivalent to one Ordinary Share, which will convert to cash at future vesting dates primarily to cover tax obligations. Separately, 1,022 Tax Obligation Awards that had vested were disposed of to the issuer at a weighted average price of JPY 4,931.4 per share, with most proceeds used for taxes and any remaining cash to be delivered to Miyabashira on July 10. Following these grants, 1,392 Tax Obligation Awards remain outstanding.
Takeda Pharmaceutical director and Chief Financial Officer Furuta Milano reported a mix of equity compensation awards and tax-related dispositions. On July 1, 2026, Milano received 12,300 Ordinary Shares as a grant, bringing direct holdings to 70,200 shares. The filing notes these restricted stock units vest in three equal annual installments beginning on June 1, 2027. Milano also received several Tax Obligation Awards, each economically equivalent to one Ordinary Share and scheduled to convert into cash at future vesting dates primarily to cover tax obligations. On July 10, 2026, 16,619 Tax Obligation Awards tied to the same number of underlying Ordinary Shares were disposed of to the issuer, with the Ordinary Shares sold at a weighted average price of JPY 4,931.5 per share to satisfy tax obligations, and any remaining proceeds to be delivered to Milano.
Platford Giles Richard reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical reported that President, IBU, Giles Richard Platford received an equity award in the form of 49,558 American Depositary Shares. The award was granted at no cash cost to him as a compensation-related grant.
The award is structured as restricted stock units, with each RSU representing a contingent right to receive one American Depositary Share. The RSUs vest in three equal annual installments beginning on July 1, 2027. After this grant, Platford directly holds 346,921 American Depositary Shares.
Smoter Jennifer Marie reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical reported that Chief Communications & Government Officer Jennifer Marie Smoter received an equity award in the form of 18,808 American Depositary Shares through a grant of restricted stock units (RSUs). Each RSU represents a contingent right to receive one ADS at no purchase price.
The RSUs vest in three equal annual installments beginning on July 1, 2027, tying the full value of the award to continued service and future vesting dates. Following this award, Smoter is shown as directly holding 18,808 ADS, reflecting a compensation-related equity grant rather than any open‑market share purchase or sale.
Ibrahim Ramy Riad Ahmed reported acquisition or exercise transactions in this Form 4 filing.
TAKEDA PHARMACEUTICAL CO LTD reported that President, PDT BU, Ramy Riad Ahmed received a grant of 25,078 American Depositary Share-based restricted stock units as equity compensation. The award was granted at no cash cost to him and increases his direct holdings to 109,865 American Depositary Shares.
The restricted stock units vest in three equal annual installments beginning on July 1, 2027, meaning the executive earns one-third of the shares each year over a three-year period, as long as the vesting conditions are met.
Greenway Nicola Deidre Petal reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical reported that Chief Human Resources Officer Nicola Deidre Petal Greenway received an equity award of 22,570 American Depositary Shares in the form of restricted stock units (RSUs). The units were granted at no cash cost to her as compensation.
Each RSU represents a contingent right to one American Depositary Share and will vest in three equal annual installments beginning on July 1, 2027. After this award, Greenway directly holds 94,406 American Depositary Shares, highlighting a meaningful ongoing equity stake that ties her compensation to Takeda’s long-term performance.
Farajallah Awny Samaan Botros reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical Chief Medical Officer Awny Samaan Farajallah received an equity grant of 17,554 American Depositary Shares as a compensation award. The award is in the form of restricted stock units, each convertible into one ADS, and vests in three equal annual installments starting on July 1, 2027. Following this grant, his direct holdings increase to 130,183 ADSs, reinforcing equity-based alignment with shareholders through a long-term vesting schedule.
Furney Natalie Anne Marie reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical’s Global General Counsel Natalie Anne Marie Furney received a compensation-related equity grant. She was awarded 43,886 American Depositary Shares on a grant basis at no cash price, increasing her direct holdings to 235,166 ADSs.
The award is structured as restricted stock units, with each RSU representing one ADS. These RSUs vest in three equal annual installments beginning on July 1, 2027, meaning the shares are delivered over time as long-term incentive compensation rather than all at once.
Pacheco Rhonda Janice reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical President, U.S. Business Unit, Rhonda Janice Pacheco received an equity grant of 50,156 restricted stock units, each representing one American Depositary Share. The award was granted at no cash cost to her as compensation rather than an open-market purchase.
The RSUs vest in three equal annual installments beginning on July 1, 2027, meaning she earns the shares over time if service conditions are met. Following this grant, she directly holds 199,408 American Depositary Shares, aligning a larger portion of her compensation with Takeda’s long-term performance.
Pignagnoli Agosti Marcello reported acquisition or exercise transactions in this Form 4 filing.
TAKEDA PHARMACEUTICAL CO LTD reported that officer Marcello Pignagnoli Agosti received an equity award in the form of 27,586 American Depositary Shares through restricted stock units. This award was granted at no cash cost to him and increases his directly held stake to 199,934 ADS.
The restricted stock units vest in three equal annual installments beginning on July 1, 2027, meaning the shares will be delivered over time as long-term compensation. This is a routine, compensation-related grant rather than an open-market purchase or sale.
Ricci Gabriele reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical’s Chief Data & Technology Officer Gabriele Ricci received an equity award of 37,616 American Depositary Shares through restricted stock units. The RSUs were granted at no cash cost and vest in three equal annual installments beginning on July 1, 2027.
Each RSU represents a contingent right to receive one American Depositary Share of Takeda Pharmaceutical Co. Ltd. Following this compensation-related grant, Ricci directly holds 196,742 American Depositary Shares, highlighting a meaningful ongoing equity stake aligned with the company’s long-term performance.
Shannon Elaine Mary reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical executive Shannon Elaine Mary, President of Global Supply & Quality, received an award of 30,094 American Depositary Shares in the form of restricted stock units. This is a compensation-related grant at a stated price of $0.00 per share, not an open‑market purchase.
Each RSU represents a contingent right to receive one American Depositary Share and will vest in three equal annual installments beginning on July 1, 2027. Following this award, Mary holds 87,674 American Depositary Shares directly, showing a larger equity stake tied to long-term performance and retention.
Duprey Lauren Rusckowski reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical granted Chief Transformation Officer Lauren Rusckowski Duprey an award of 45,140 restricted stock units, each representing one American Depositary Share, at no cash price. The RSUs vest in three equal annual installments beginning on July 1, 2027. Following this equity award, she directly holds 273,643 American Depositary Shares.
Bitetti Teresa Marie reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical reported that Teresa Marie Bitetti, President of its Oncology Business Unit, received an equity award of 43,886 American Depositary Shares (ADSs) in the form of restricted stock units (RSUs). Each RSU represents the right to receive one ADS if vesting conditions are met.
The RSUs vest in three equal annual installments beginning on July 1, 2027, which means the award is tied to continued service over several years. After this grant, Bitetti directly holds 302,022 ADSs, reflecting her ongoing long-term ownership stake aligned with shareholders.
Kim Julie So-Young reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical President and CEO Julie Kim reported equity compensation awards rather than market purchases or sales. On July 1, 2026, she received 22,800 Ordinary Shares and an award of 50,434 restricted stock units (RSUs), each RSU representing one American Depositary Share.
The RSUs tied to American Depositary Shares vest in three equal annual installments beginning on July 1, 2027. Following this grant, her directly held American Depositary Shares increased to 480,579.
She also received three Tax Obligation Awards covering 7,743, 7,741, and 7,741 Ordinary Shares, each economically equivalent to one Ordinary Share. These awards vest and are payable in cash primarily to cover tax obligations, with vesting dates in 2027, 2028, and 2029.
Plump Andrew Stewart reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical President of R&D Andrew Stewart Plump reported a new equity award in the form of restricted stock units (RSUs). He received 125,390 RSUs, each representing a contingent right to receive one American Depositary Share, as a compensation grant at no purchase price.
The RSUs vest in three equal annual installments beginning on July 1, 2027, meaning the award will be delivered over three years if vesting conditions are met. After this grant, he directly holds 931,962 American Depositary Shares and indirectly holds 281,307 American Depositary Shares through a trust.
Takeda Pharmaceutical’s President and CEO Christophe Weber received new equity-based compensation awards. On April 27, 2026 he was granted 165,370 American Depositary Shares and 78,900 Ordinary Shares at no cash cost, described as grant or award acquisitions.
The filing notes these awards stem from restricted stock units granted on July 1, 2023, whose final amounts were set by the Compensation Committee based on performance metrics including core revenue, core operating profit and important R&D milestones. Following these grants, Weber directly holds 418,803 American Depositary Shares and 1,014,200 Ordinary Shares.
He also received 78,978 Tax Obligation Awards, each economically equivalent to one Ordinary Share and settling in cash primarily to cover tax obligations at the then-current Ordinary Share market price. After this grant, he holds 125,345 Tax Obligation Awards, alongside additional RSU positions scheduled to vest between 2026 and 2028.
Furuta Milano reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical director and Chief Financial Officer Furuta Milano received equity-based compensation rather than buying shares on the market. On April 27, 2026, Milano was awarded 7,800 Ordinary Shares at no cost following performance-based RSUs tied to core revenue, core operating profit, and R&D milestones, bringing direct ownership to 57,900 Ordinary Shares.
The filing notes that this total includes 27,300 restricted stock units (RSUs), which are scheduled to vest as Ordinary Shares on June 1, 2026 (16,200 shares), June 1, 2027 (7,100 shares) and June 1, 2028 (4,000 shares). Milano also received 7,814 Tax Obligation Awards, economically equivalent to Ordinary Shares but payable in cash at vest primarily to cover tax obligations, with 16,619 such derivative awards held afterward.
Plump Andrew Stewart reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical Co. Ltd. director and President of R&D Andrew Stewart Plump reported a compensation-related equity award. On April 27, 2026, he was credited with 212,470 American Depositary Shares at $0.00 per share as a grant/award linked to earlier restricted stock units.
The award stems from RSUs originally granted on July 1, 2023, which vest in ADSs based on performance metrics including core revenue, core operating profit, and key R&D milestones. After the award, he directly holds 806,572 ADS and indirectly holds 281,307 ADS through a trust. The filing notes unvested RSUs scheduled to vest on July 1, 2026 (329,478 shares), July 1, 2027 (91,580 shares), and July 1, 2028 (43,374 shares), each representing a contingent right to receive one ADS.
Ricci Gabriele reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical granted Chief Data & Technology Officer Gabriele Ricci 34,994 American Depositary Shares on April 27, 2026 as a compensation-related award. This follows a July 1, 2023 grant of restricted stock units tied to performance metrics such as core revenue, core operating profit and important R&D milestones.
After this award, Ricci holds 159,126 American Depositary Shares, including 80,768 restricted stock units. These RSUs are scheduled to vest in tranches on July 1, 2026, July 1, 2027 and July 1, 2028, reflecting a multi‑year incentive structure rather than an open‑market transaction.
Takeda Pharmaceutical reported that President, OBU Teresa Marie Bitetti acquired 64,988 American Depositary Shares at no cost through a performance-based equity award. These shares reflect restricted stock units granted on July 1, 2023, with the final amount determined on April 27, 2026 based on core revenue, core operating profit, and R&D milestones.
Following this award, Bitetti holds 258,136 American Depositary Shares, including 150,790 restricted stock units that will vest in stages on July 1, 2026, July 1, 2027, and July 1, 2028, tying a substantial portion of her compensation to Takeda’s future performance.
Takeda Pharmaceutical Co Ltd Chief Transformation Officer Lauren Rusckowski Duprey received an equity award tied to performance goals. On April 27, 2026, she was granted 59,990 American Depositary Shares at a price of $0.00 per share as a grant or award acquisition.
After this award, she directly holds 228,503 American Depositary Shares, including 146,762 restricted stock units that may convert into shares. These RSUs vest on a schedule: 100,658 shares on July 1, 2026, 30,488 shares on July 1, 2027, and 15,616 shares on July 1, 2028, contingent on prior performance metrics such as core revenue, core operating profit, and important R&D milestones.
Kim Julie So-Young reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical reported that CEO-elect Julie So-Young Kim received a grant of 105,416 American Depositary Shares (ADS) on April 27, 2026, following performance-based RSU metrics set from a July 1, 2023 award. After this grant, she holds 430,145 ADS, including 256,372 RSUs that vest in stages from July 1, 2026 through July 1, 2028.
Platford Giles Richard reported acquisition or exercise transactions in this Form 4 filing.
Takeda Pharmaceutical executive Giles Richard Platford, President IBU, received a grant of 72,124 American Depositary Shares on April 27, 2026 as a performance-based restricted stock unit (RSU) award at no cash cost to him.
The award was determined by the Compensation Committee using performance metrics including core revenue, core operating profit and important R&D milestones from an RSU grant originally made on July 1, 2023. Following this award, Platford directly holds 297,363 American Depositary Shares, including 166,744 RSUs scheduled to vest on July 1, 2026 (116,762 shares), July 1, 2027 (32,396 shares) and July 1, 2028 (17,586 shares).